Andrew Taylor and Nick Warren have contributed the foreword to e-Competitions’ latest special issue on healthcare. The article reviews a wide range of antitrust and merger cases in the European health sector in recent years, and identifies several common themes. These include the tension between the application of competition law to suppliers of healthcare services…
Andrew Taylor and Nick Warren have featured in the December edition of the Competition Policy International (CPI) Antitrust Chronicle. In their article, the authors review CMA’s interventions in mergers of UK grocery retailers and conclude that despite recent revisions to its approach of weighting competition in local markets any large-scale consolidation in UK grocery retailing seems…
Combination therapies use two or more drugs as part of a single treatment regime for an increasing number of diseases, such as cancer. Combination treatments can deliver better outcomes for patients by targeting a disease via multiple pathways or at multiple levels. Unfortunately, there are a number of barriers to making combination therapies more widely…
Andrew Taylor has been featured in two leading industry titles – Private Equity News and Real Deals – discussing the Montagu acquisition of Capita’s school management software business, a deal worth £400m. Andrew comments on the level of interest that the Competition and Markets Authority might take, considering it likely to take a close look…
Competition authority intervention in digital & tech markets is gathering pace both internationally and in the UK. The US Department of Justice has launched its long awaited lawsuit against Google, the European Commission is investigating Amazon and Apple, and the UK’s Competition & Markets Authority (CMA) has said that it will open investigations into Facebook…
Guides, White Papers & Research
Buy-and-Build Strategies: Managing the risk of UK Competition and Markets Authority intervention
This paper draws on our experience as former competition regulators, and our research on buy-and-builds, to identify opportunities that can mitigate the risk of CMA intervention for these platforms.
It contains practical advice around:
- The likelihood of deals being called-in by the CMA
- Influencing the CMA’s view of a market
- How to best engage with the CMA
- Drivers of CMA review costs
Fill in your details to receive your copy:
We will never share your details with anyone.